Keytruda Slashes Death Risk by 78% in Japanese Head and Neck Cancer Patients

2019 JSMO Annual Meeting is being held in Kyoto on July 18-20 MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) demonstrated a hefty 78% reduction in the risk of deaths when used in a first-line setting in Japanese patients with relapsed/metastatic head and...read more